Strike three: Bris­tol-My­ers’ third I/O shot at glioblas­toma miss­es as Op­di­vo flops yet again on key end­point

Glioblas­toma con­tin­ues to de­fy about every­thing thrown at it.

Bris­tol-My­ers Squibb put out word Thurs­day morn­ing that its third Phase III as­sault on brain can­cer us­ing its star PD-1 Op­di­vo failed the first end­point, with no sig­nif­i­cant im­prove­ment in pro­gres­sion-free sur­vival for pa­tients who face grim odds.

Check­Mate-548 ap­pears head­ed for a com­plete col­lapse, though over­all sur­vival is still be­ing stud­ied. Re­searchers had tried to see if the check­point ther­a­py could out­do the stan­dard of care by adding it to the stan­dard — temo­zolo­mide and ra­di­a­tion ther­a­py. 

They al­ready tried — and failed — ear­li­er this year with Check­Mate-498, a Phase III that com­bined Op­di­vo and ra­di­a­tion against temo­zolo­mide. That tri­al failed the mark on OS in May.

Two years ago the com­pa­ny was forced to con­cede de­feat on Check­mate-143, the first use of a PD-1 against glioblas­toma.

Bris­tol-My­ers has had a string of set­backs in the clin­ic with Op­di­vo, though the phar­ma gi­ant still en­joys block­buster rev­enue even as Mer­ck’s Keytru­da con­tin­ues its clin­i­cal blitz that put them on top of the mar­ket.

In this case, though, the Bris­tol-My­ers team joins a long list of fail­ures in fight­ing brain can­cer, which re­mains one of the tough­est tar­gets in on­col­o­gy. Ab­b­Vie had its own bit­ter set­back to re­port in May when their an­ti­body-drug con­ju­gate de­patux­izum­ab mafodotin (or de­patux-m; pre­vi­ous­ly known as ABT-414) al­so failed in im­prov­ing sur­vival times for brain can­cer vic­tims.

Sev­er­al years ago Ab­b­Vie showed up at AS­CO with ABT-414 and Ro­va-T to tout their po­ten­tial. Ro­va-T failed com­plete­ly for the R&D team, forc­ing a com­plete write-off of a drug they bought for $5.8 bil­lion up­front.

Robert Prins UCLA

A com­plete fail­ure here won’t ex­tin­guish all hope that a PD-1 could yet play a role in glioblas­toma. Robert Prins at the UCLA Jon­s­son Com­pre­hen­sive Can­cer Cen­ter re­port­ed ev­i­dence ear­li­er this year from a tiny ex­plorato­ry tri­al that a check­point may help pa­tients when used ahead of surgery. But it’s a long shot.

One of the few re­main­ing Phase III stud­ies for glioblas­toma like­ly to read out soon be­longs to Toca­gen $TO­CA which is mak­ing the dif­fi­cult as­sault with To­ca 511/FC. Re­searchers an­nounced sev­er­al months ago that they would con­tin­ue to the fi­nal read­out, dash­ing any hopes for an ear­ly suc­cess. There isn’t much con­fi­dence in this drug, though, with the stock falling from a high north of $15 last fall to just above $3 a share this morn­ing. The mar­ket cap is hold­ing at a mi­cro-lev­el $72 mil­lion.

These fail­ures won’t en­cour­age oth­ers to make a try.

Aerial view of Genentech's campus in South San Francisco [Credit: Getty]

Genen­tech sub­mits a big plan to ex­pand its South San Fran­cis­co foot­print

The sign is still there, a quaint reminder of whitewashed concrete not 5 miles from Genentech’s sprawling, chrome-and-glass campus: South Francisco The Industrial City. 

The city keeps the old sign, first erected in 1923, as a tourist site and a kind of civic memento to the days it packed meat, milled lumber and burned enough steel to earn the moniker “Smokestack of the Peninsula.” But the real indication of where you are and how much has changed both in San Francisco and in the global economy since a couple researchers and investors rented out an empty warehouse 40 years ago comes in a far smaller blue sign, resembling a Rotary Club post, off the highway: South San Francisco, The Birthplace of Biotech.

Here comes the oral GLP-1 drug for di­a­betes — but No­vo Nordisk is­n't dis­clos­ing Ry­bel­sus price just yet

Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.

Rybelsus will be the first GLP-1 pill to enter the type 2 diabetes market — a compelling offering that analysts have pegged as a blockbuster drug with sales estimates ranging from $2 billion to $5 billion.

Ozempic, the once-weekly injectable formulation of semaglutide, brought in around $552 million (DKK 3.75 billion) in the first half of 2019.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

Oxitec biologist releases genetically modified mosquitoes in Piracicaba, Brazil in 2016 [credit: Getty Images]

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

When the hysteria of Zika transmission sprang into the American zeitgeist a few years ago, UK-based Oxitec was already field-testing its male Aedes aegypti mosquito, crafted to possess a gene engineered to obliterate its progeny long before maturation.

But when a group of independent scientists evaluated the impact of the release of these genetically-modified mosquitoes in a trial conducted by Oxitec in Brazil between 2013 and 2015, they found that some of the offspring had managed to survive — prompting them to speculate what impact the survivors could have on disease transmission and/or insecticide resistance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

[via AP Images]

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

There are two updates on the lawsuit against Purdue Pharma over its role in fueling the opioid epidemic, as the Sackler family threatens to walk away from their pledge to pay out $3 billion if a bankruptcy judge does not stop outstanding state lawsuits against them. At the same time, the company has asked permission to pay millions in bonuses to select employees.

Purdue filed for chapter 11 bankruptcy this week as part of its signed resolution to over 2,000 lawsuits. The deal would see the Sackler family that owns Purdue give $3 billion from their personal wealth and the company turned into a trust committed to curbing and reversing overdoses.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA.